Contact Congress about S. 3716: RARE Act

Rare-disease drugs would keep seven years of protection from direct competition, but only for their exact approved use. The new rule would cover both past and future drug approvals.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

RARE Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 3716: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects people with rare diseases and the companies that develop their treatments. Patients could see more treatment choices if the FDA can approve drugs for different uses sooner. Drug makers could face more competition and may change how they plan research and approval requests. The FDA would have to apply the narrower rule to both old and new drug approvals.

Why this matters: One narrow drug approval can now protect a wider rare-disease market from matching drugs. This bill would limit that protection to the exact approved use. That could make room for more treatment choices and competition. It could also reduce the reward companies receive for developing rare-disease drugs. Because the rule would cover older approvals, it may also change current business plans and pending FDA applications.

Key provisions in S. 3716

• The seven-year protection would cover only a drug’s exact approved use. It would no longer cover every use for the same rare disease.
• The bill changes Section 527, the part of federal food and drug law that sets this protection. It replaces references to the same disease with references to the same approved use.
• When the FDA compares a later drug with a protected drug, it must focus on the exact use covered by the seven-year period. That use must match for the drugs to count as the same.
• The FDA must judge whether a later drug meets patient needs for the exact approved use. The bill adds that focus directly to the law.
• An “approved use or indication” means the exact medical use approved for an orphan drug. Section 505 covers regular drug approvals, while Section 351 of the Public Health Service Act covers licenses for biologic medicines.

How Modern Action helps you take action on S. 3716

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 3716

What is S. 3716?

Rare-disease drugs would keep seven years of protection from direct competition, but only for their exact approved use. The new rule would cover both past and future drug approvals.

How do I support or oppose S. 3716?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 3716?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 3716?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.